Are both PIVKA-II and α-fetoprotein necessary in follow-up management after hepatic resection for hepatocellular carcinoma?

Hepato-Gastroenterology

Volumn 49, Issue 48, 2002, Pages 1615-1618

  Koh, T ^a   Taniguchi, H ^a   Katoh, H ^a   Kunishima, S ^a   Yamaguchi, A ^a   Yamagishi, H ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

AFP; HCC; PIVKA II; Recurrence

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROTEIN PRECURSORS; PROTHROMBIN; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0036841339     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Matsumata T, Kanematsu T, Shirabe K, Sonoda T, Furuta T, Sugimachi K: Decreased morbidity rates in surgical patients with hepatocellular carcinoma. Br J Surg 1990; 77:677-680.
2. The Liver Cancer Study Group of Japan: Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 1994; 74:277-2780.
3. Shimada M, Matsumata T, Taketomi A, Yamamoto K, Itasaka H, Sugimachi K: Repeat hepatectomy for recurrent hepatocellular carcinoma. Surgery 1994; 115:703-706.
4. Bismuth H, Houssin D, Ornowski J, Meriggi F: Liver resections in cirrhotic patients: a Western experience. World J Surg 1986; 10:311-317.
5. Kanematsu T, Shirabe K, Sugimachi K: Surgical strategy for primary hepatocellular carcinoma associated with cirrhosis. Sem Surg Oncol 1990; 6:36-41.
6. Fujiyama S, Morishita T, Sagara K, Sato T, Motohara K, Matsuda I: Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma. hepatogastroenterology 1986; 33:201-205.
7. Fujiyma S, Morishita T, Hashiguchi O, Sato T: Plasma abnormal prothrombin (des-γ-carboxy prothrombin) as a marker of hepatocellular carcinoma. Cancer 1988; 61:1621-1628.
8. Nakao A, Suzuki Y, Isshiki K, Kimura Y, Takeda S, Kishimoto H, et al: Clinical evaluation of plasma abnormal prothrombin (des-γ-carboxy prothrombin) in hepatobiliary malignancies and other diseases. Am J Gastoenterol 1991; 86:62-66.
9. Suehiro t, Matsumata T, Itasaka H, Taketomi A, Yamamoto K, Sugimachi K: Des-gammma-carboxy prothrombin and proliferative activity of hepatocellular carcinoma. Surgery 1995; 117:682-691.
10. Sakon M, Monden M, Gotoh M, Kansai T, Umeshita K, Nakano Y, et al: Relationship between pathologic prognostic factors and abnormal levels of des-α-carboxy prothrombin and α-fetoprotein in hepatocellular carcinoma. Am J Surg 1992; 163:251-256.
11. Scudamore CH, Ragaz J, Kluftinger AM, Owen DA: Hepatocellular carcinoma: a comparison of oriental and Caucasian patients. Am J Surg 1988; 155:659-662.
12. Sutton FM, Russell NC, Guinee VF, Aipert E: Factors affecting the prognosis of primary liver carcinoma. J Clin Oncol 1988; 6:312-328.
13. Nomura F, Ohnishi K, Tanabe Y: Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels: analysis of 606 patients. Cancer 1989; 64:1700-1706.
14. Shirabe K, Kanematsu T, Matsumata T, Adachi E, Akazawa K, Sugimachi K: Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy. Hepatology 1991; 14:802-805.
15. Nagao T, Inoue S, Yoshimi F, et al: Postoperative recurrence of hepatocellular carcinoma. Ann Surg 1990; 211:28-33.
16. Yamanaka N, Okamoto E, Toyosaka A, et al: Prognostic factors after hepatectomy for hepatocellular carcinoma: A univariate and multivariate analysis. Cancer 1990; 65:1104-1110.